Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $284.35M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.18M
Average 0.11M
Returns on capital
Benitec Biopharma Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-39.0%
avg -976.0%
ROIC
-42.6%
avg -296.8%
ROA
-38.1%
avg -103.2%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -103.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jerel A. Banks | Executive Chairman & Chief Executive Officer | AUD 1.26M | 51 | 450.00K | 1.71% |
Sophie Mukadam | Chief Operating Officer | AUD 870.44K | 45 | 500.00K | 1.90% |
Megan Joan Boston | CFO & Secretary | AUD 833.04K | 54 | — | — |
Michael Graham | Head of Discovery & Founding Scientist | AUD 135.96K | — | — | — |
Claudia Kloth | Senior Vice President of Manufacturing | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 18, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$2.44M
Sells
0
$0.00
Net Transaction Value
+$2.44M
Net buying
Most Active
SUVRETTA CAPITAL MANAGEMENT, LLC
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 29, 25Dec 29, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $155.7K$155,729.28 |
| Dec 29, 25Dec 29, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $884.4K$884,352.00 |
| Dec 26, 25Dec 26, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $187.6K$187,592.00 |
| Dec 26, 25Dec 26, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $33K$32,959.60 |
| Dec 23, 25Dec 23, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $95.1K$95,090.00 |
| Dec 23, 25Dec 23, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $547.4K$547,410.00 |
| Dec 22, 25Dec 22, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $34.9K$34,935.36 |
| Dec 22, 25Dec 22, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $201.1K$201,132.00 |
| Dec 19, 25Dec 19, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $160.1K$160,146.00 |
| Dec 19, 25Dec 19, 2025 | SUVRETTA CAPITAL MANAGEMENT, LLC Indirect | Buy | $27.9K$27,942.32 |
1–10 of 12
Summary
Insiders reported 12 buys worth $2.44M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.44M. SUVRETTA CAPITAL MANAGEMENT, LLC was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Benitec Biopharma Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about BNTC's management, answered from reported figures.
Who manages BNTC?
Benitec Biopharma Inc. (BNTC) lists 5 active executives. The top listed executive is Claudia Kloth, Senior Vice President of Manufacturing.
Are BNTC insiders buying or selling?
Recent insider activity shows net buying of $99.87M.
Continue the stock analysis
Jump to another research area for this company.